| BID | 53.79 | ASK | 53.99 | ||
| Open | 53.73 | Previous Close | 53.25 | ||
| Pre-Market | 54.39 | After-Market | - | ||
| 0.38 0.70% | - - |
| Target Price | 63.85 | Analyst Rating | Strong Buy 1.33 | |
| Potential % | 18.22 | Finscreener Ranking | ★★★ 49.75 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★ 42.93 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★★★ 59.68 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | ☆ 23.91 | |
| Market Cap | 141.75B | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 62.04 | Earnings Date | 11th Feb 2021 |
Today's Price Range 53.5954.21 | 52W Range 36.1564.94 | 5 Year PE Ratio Range 19.2074.90 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.74% | ||
| 1 Month | 11.31% | ||
| 3 Months | 1.77% | ||
| 6 Months | -2.45% | ||
| 1 Year | 9.41% | ||
| 3 Years | 47.45% | ||
| 5 Years | 75.11% | ||
| 10 Years | 187.62% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 16.80 | |||
ROE last 12 Months | 19.75 | |||
ROA (5Y Avg) | 4.23 | |||
ROA last 12 Months | 3.92 | |||
ROC (5Y Avg) | 10.05 | |||
ROC last 12 Months | 10.73 | |||
Return on invested Capital Q | 2.67 | |||
Return on invested Capital Y | 7.40 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 55.30 | ||||
| 11.31 | ||||
| 7.74 | ||||
| 31.50 | ||||
| -41.80 | ||||
| 1.67 | ||||
| -6.85 | ||||
| 4.65 | ||||
| 154.03B | ||||
| Forward PE | 20.55 | |||
| PEG | 3.29 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.40 | ||||
| 1.00 | ||||
| 0.61 | ||||
| 1.83 | ||||
| 3.30 | ||||
| Leverage Ratio | 5.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 80.10 | ||||
| 16.60 | ||||
| 32.00 | ||||
| 9.40 | ||||
| 11.14 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 18.32B | ||||
| 6.98 | ||||
| -1.62 | ||||
| -1.00 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.67 | ||||
| 0.90 | ||||
| 0.00 | ||||
| 0.00 | ||||
| Payout ratio | 167.00 |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2020 | 0.49 | 0.47 | -4.08 |
| Q02 2020 | 0.44 | 0.48 | 9.09 |
| Q01 2020 | 0.47 | 0.53 | 12.77 |
| Q04 2019 | 0.53 | 0.45 | -15.09 |
| Q03 2019 | 0.45 | 0.50 | 11.11 |
| Q02 2019 | 0.30 | 0.73 | 143.33 |
| Q01 2019 | 0.43 | 0.45 | 4.65 |
| Q04 2018 | 0.73 | 1.58 | 116.44 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2020 QR | 0.53 | -3.64 | Negative |
| 12/2020 QR | 0.55 | 3.77 | Positive |
| 12/2020 FY | 2.01 | -0.50 | Negative |
| 12/2021 FY | 2.59 | 0.78 | Positive |
| Next Report Date | 11th Feb 2021 |
| Estimated EPS Next Report | 0.53 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | 16.80 |
| Volume Overview | |
|---|---|
| Volume | 13.71M |
| Shares Outstanding | 2.62B |
| Trades Count | 73.25K |
| Dollar Volume | 712.43M |
| Avg. Volume | 12.58M |
| Avg. Weekly Volume | 13.71M |
| Avg. Monthly Volume | 12.57M |
| Avg. Quarterly Volume | 10.50M |
Astrazeneca PLC (NYSE: AZN) stock closed at 54.01 per share at the end of the most recent trading day (a 1.43% change compared to the prior day closing price) with a volume of 13.74M shares and market capitalization of 141.75B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 64600 people. Astrazeneca PLC CEO is Pascal Soriot.
The one-year performance of Astrazeneca PLC stock is 9.41%, while year-to-date (YTD) performance is 8.04%. AZN stock has a five-year performance of 75.11%. Its 52-week range is between 36.15 and 64.94, which gives AZN stock a 52-week price range ratio of 62.04%
Astrazeneca PLC currently has a PE ratio of 55.30, a price-to-book (PB) ratio of 11.31, a price-to-sale (PS) ratio of 7.74, a price to cashflow ratio of 31.50, a PEG ratio of 2.32, a ROA of 3.92%, a ROC of 10.73% and a ROE of 19.75%. The company’s profit margin is 11.14%, its EBITDA margin is 32.00%, and its revenue ttm is $18.32 Billion , which makes it $6.98 revenue per share.
Of the last four earnings reports from Astrazeneca PLC, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.53 for the next earnings report. Astrazeneca PLC’s next earnings report date is 11th Feb 2021.
The consensus rating of Wall Street analysts for Astrazeneca PLC is Strong Buy (1.33), with a target price of $63.85, which is +18.22% compared to the current price. The earnings rating for Astrazeneca PLC stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Astrazeneca PLC has a dividend yield of 1.67% with a dividend per share of $0.90 and a payout ratio of 167.00%.
Astrazeneca PLC has a Buy technical analysis rating based on Technical Indicators (ADX : 11.91, ATR14 : 3.02, CCI20 : 195.36, Chaikin Money Flow : 733.89, MACD : 0.47, Money Flow Index : 64.54, ROC : 7.61, RSI : 70.62, STOCH (14,3) : 95.23, STOCH RSI : 1.00, UO : 62.74, Williams %R : -4.77), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Astrazeneca PLC in the last 12-months were: Michel Demare (Buy at a value of $102 382), Nazneen Rahman (Buy at a value of $39 698), Philip A J Broadley (Buy at a value of $99 888), Tony Mok (Buy at a value of $172 640)
Astrazeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology, and neuroscience. The majority of sales come from international markets with the United States representing close to one third of its sales.
CEO: Pascal Soriot
Teplephone: +44 2037495000
Address: 1 Francis Crick Avenue, Cambridge CB2 0AA, , GBR
Number of employees: 64 600
